Search | Clinical Trials Finder

Conditions: Metastatic Sarcoma, Radiation Therapy Patient, Ewing Sarcoma, Rhabdomyosarcoma
Interventions: Consolidative radiation therapy (cRT); Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 39 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Minneapolis, Minnesota

Conditions: Cardiac Rehabilitation, Exercise, Quality of Life
Interventions: KardioPAC Mobile Application, Standard of Care; Behavioral · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Systemic Lupus Erythematosus
Interventions: Telitacicept, Placebo; Biological
Lead sponsor: Vor Biopharma; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Anniston, Alabama • Mission Hills, California • Orange, California + 9 more

Conditions: Depressive Disorder, Major
Interventions: Prism Training; Device
Lead sponsor: GrayMatters Health Ltd.; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Providence, Rhode Island • Houston, Texas

Conditions: Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions: Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide; Drug
Lead sponsor: Leaf Vertical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Prostate Cancer (Adenocarcinoma)
Interventions: Brachytherapy; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 40 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Flexion Contracture
Interventions: KneeMD; Device
Lead sponsor: Anne Arundel Health System Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Annapolis, Maryland

Conditions: Colorectal Cancer
Interventions: Telisotuzumab Adizutecan, Standard of Care; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more

Conditions: Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection, Mycoplasma Genitalium Infection
Interventions: cobas® liat CT/NG/MG nucleic acid test, Standard of Care (SOC): Clinician's Standard Practice; Diagnostic Test · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: San Francisco, California • Hamilton Square, New Jersey • Perth Amboy, New Jersey + 1 more

Conditions: Advanced Solid Tumors
Interventions: ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel; Biological · Drug
Lead sponsor: AskGene Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: New York, New York • Pittsburgh, Pennsylvania

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cancer
Interventions: Chaplain-Provided Spiritual Care, Psychotherapy and Meditation Intervention; Behavioral
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Carcinoma
Interventions: Best Practice, Computed Tomography, Electronic Health Record Review, Imaging Procedure, Questionnaire Administration, Radiation Therapy; Other · Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more

Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Interventions: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: HIV Infections
Interventions: VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20; Biological · Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more

Conditions: ECRB Tendinopathy
Interventions: Semiconductor Embedded Therapeutic Arm Sleeves, Placebo Arm Sleeves, Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections; Device · Other
Lead sponsor: INCREDIWEAR HOLDINGS, INC.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Endometrial Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 29
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more

Conditions: Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury, Pulmonary Arterial Hypertension, Cardiovascular Diseases
Interventions: [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging; Drug · Diagnostic Test
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Pressure Ulcers
Interventions: PuraPly® Antimicrobial Wound Matrix, SOC for Pressure Ulcers; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Lake Success, New York • Mineola, New York

Conditions: Vaping
Interventions: Discussion of point-of-care ultrasound lung findings; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Bladder Cancer
Interventions: Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: Lawrence Fong; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Systemic Lupus Erythematosus
Interventions: Telitacicept, Placebo; Biological · Drug
Lead sponsor: Vor Biopharma; Industry
Eligibility: 12 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Hemet, California • Menifee, California • Rockford, Illinois + 1 more

Conditions: Dysphagia, Stroke, Parkinson Disease
Interventions: In-person sEMG-biofeedback, Remote sEMG-biofeedback, Standard-of-care treatment; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 50 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Champaign, Illinois • West Lafayette, Indiana

Conditions: Metabolic Syndrome, Pre-Diabetes
Interventions: Time Restricted Eating + Standard of Care, Standard of Care; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Investigating KardioPAC Mobile App to Improve Physical Fitness Among Cardiac Rehabilitation Patients

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

Effectiveness of KneeMD on Flexion Contracture in Total Knee Arthroplasty Patients

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

Point-of-Care Ultrasound (POCUS) Findings and Impact on Vaping

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

The Influence of Time-Restricted Eating in Patients With Metabolic Syndrome